HUE028954T2 - Heterociklusos vegyületek és alkalmazásuk - Google Patents
Heterociklusos vegyületek és alkalmazásuk Download PDFInfo
- Publication number
- HUE028954T2 HUE028954T2 HUE08727163A HUE08727163A HUE028954T2 HU E028954 T2 HUE028954 T2 HU E028954T2 HU E08727163 A HUE08727163 A HU E08727163A HU E08727163 A HUE08727163 A HU E08727163A HU E028954 T2 HUE028954 T2 HU E028954T2
- Authority
- HU
- Hungary
- Prior art keywords
- mmol
- nrara
- chloro
- mixture
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (5)
- HEi^Kociiassos vegyöleter is âijkalmazAsus: lëabaàÂti %éæyps3stbk 1, Á:k8yfeíkex§ :SKsrks2eís %iáiSÍ«ííÍ vëgyfe::vagy hàrë^y.gyôgyàmft%g'©îfesgÂaté mÿi, akd ,X: jelzésé 00^ X; jdentésebí' V jelentéseN(R!l},()vagyS; Z MeÄeCES-agyN:; & értéke 0. %, 2 mg y 3; S! jebatése közvetlen kíáessel vagy ^sg^«^«fe^í-^s!Sö|ó# tÄst, resafeea-fölítea vagy tetíRtkax Ss '&· vagy /-tagú. N, O vagy S kézül választott ö,. 1, 2, 3 vagy 4 atomot taiíaítnasó, dg egynél több O vagy S gtomaknom tartalmazó msjoocik&i«? akti a §y#rü Eqzsiprbéíö széttâtottïiai 0, 1 vagy 2 φχο vagy ioxo csoporttal szabsztít»altak. aWagyíírú 0 vagy l R? saxbs^tteRaseí sstobsztitnáít. és a gyűrű tovább sssabsztitnák % 1, 2 vagy 3 ssobsztónopásd, aiKeîî^k'.«^àsÈÂ'%^fe^i' a kővetkezők kézül választottak: bab, intro, oiano, C^albt, OCs.^«, OC^hsbdkii, és q^kaloaÄ R2 jelentése bab, G.Jukxdkíl ciaao, nitro. -CÍ~0}R<!, -a<>)OR\ -QK>)NR*R*, -Ct-lsR^N^R3, -OR*, -ocb-o)R\ -ocqopÄ -oe^MW$í*:0^ ~SRS, -s<*o)R*, -S(<>)2r, -SbCOxN^R'', •${-0}jN(R;,}C(K)}Rt>: ·ΚΕ;Έ;', ••NíR^K:;{<).íOR\ -ΗίΕ^ό^Ρ^» -NÍR’jC^T'^NR'R*, -NíR*)S{K>hR8s «^slk|er és ÄC^aiyiö^köaäl válasrtc·«; vagy Ra jelentése C,*a!ldl, lepik tesal, teroarsi teroelklos, -^jalkil^ewpasl ^CMÄi)hetaöÄ$, -<3(e|.:3Äii}haioroadi,; aíCi.yiMl^etertícikte -Mqet,jatkil}batomartk Ä|Ct.;;aM13bobtxtciksos, ,(Ç.paMpi«i, -ÖiC,.#;-és -ME3CC:.3áM|&si MbM választott, arndyek «iaé^tfee 0, 1, 2 vagy I szebszíttitcfissel srabsznatsH, antety Cí .«hsloalkik OCiaslkik Br, Cl, P, Î és C:.4aikít közül választott; R3 jelentése H, hé* Ct4MmMl attno, nitro, -CH»R*, -CK>)GR\ -C<-0)M<sRs, -C{»NR*)NR*R*, -OR*, -OCó- 0)R\ -0C(«0)NR*R*, -0€{-0}Ν(Β8)$(=<);·:»Ε;). -OC^Uk0MRÄRÄ, -OC^alRilOR3, -Síi5, -S(0)R* -S(==0),R3, ~SbO}5RR*R\ -S(-Ô3>N{R5)C(-0)RX -S{-0)iN(B.a}C(-0)HRsRs, ÄSR\ -N(R*)C{*0)R*, PirjGHïpE5, -N(RstC(»t.)pRsR5, -ifiP« -N{R*)$H>)jR\ -NtROSC-öi-NR^R3, «IJIÄBn -RR^^itiMiOR3 C;.^!kii, tont!, benztk heteroarik és heterodk- lus közül vámmii, ám » C^lfeR, toMvUtteni# és feetenscifelus tovább szübsztlmált % 3,, 2 3 szubsztituenssel, amely C) .ploslkíl, OC-^aikik Br, Cl, F, 3 cs C^-sikH közöl választót;; R4 jeiontése nimden esetben, egymástól föggetletmL bak;, nitro, eiano, €(..ριΜ1, OCt.$a!kií, ÖC^baioalkil, N'HC')...ia;kjl, N(C;.4aikil)C:,4alktl vagy Ci.pdoalkil; Is jelentése miacfeu essifcesï,; egymástól függetlenül, B, Si; Ci,sÄk €},patoaI3al, vagy Ci^aMl 1, 2 vagy 3 sxubszístoeassol szifesztkuák. amely hale, e;ar,o, OH, OC'i^alkk, CPalkii, Ctohaloalkil, OCj ^alkiS, NH2, Ni;C;.,:alkiL ííP^álktpG^M közöl válássá*««; vagy mindkét RÍ csoport együtt C^sptroaikii csoportot alkot, amely ü, 1, 2 vagy 3· szubszdtuenssel .^abssáeA graety sgabs^ltuoíts tío, dano, OH., OCMaik!k Cj 4alMl, O, oíMoalktl, fX^ksí, WCt ^ÄfÄÄil vMaszfelt; R8 jsleaiése H, halo, 0;i,salki, Cf^haloatkik ciano, nkro, -C{“-'Ö)R\ -k;{ '0)0R\ *C('::0)Nk''Re, C(:-N.R‘> KR8R:\ -S(--Ö)R\ -S{= 0}>RS, -S(-€%NR.8R8, -S(«Oj,N(Ral€0-0)R:i, -StpO^CR^e^OlOR8, -S(-Ô)>N-(RíjCÍ-OlkíR^R* közöl választott; Rí jeleotése M, haló, C(,galkti £f .«haindkii, ®iano, nitro, .Ç{“R)}R8 4d^ö)(lR'·, X(~NRÍ)-· NR8R8, -Sfe€>)E\ ~S(-0}>Rs, -%0}sNÄ ~$ί~0)2Π- (Rs)C;-05BRaRs közRl vákisztoít; Is jblemése !!:, pjtsioalkíl,:B*,Cl, F, 3, ÖR* BR*R*.:C^sMî» IstÄ berni, heteroarlésbeterooíklas közül választott, ahol & C^&lMh Jeni,. bemal, heteroazíl ;ós heteroctkáus tovább szabsztitaált Ö, .1,2 vagy 3 szs^. szíjtucnssd, amely Cj.jhaloaifcii, Bt, CL F, 1 és iCj^alkti közül választott; R® }de»tése H, haló, C;..:haioalkil, cisno, nitro, ·€ό::0)Κ3, -€(=-Ö)OR8XpO)NR3R3, -GÍ-MR^MSÍSÍ, -ÖR", -0C(-'Oííi8, -OCPÖ)NR*R\ -OCC-OlNCriSC-OkR8, -OC^aik'iiÄ* -OC^aíídlOR8, ·«* -SpÖ)!3, -8{-0};;Rs: -8{-Οί>ΝΠ:\ - 8Ρ0);Ν(|13)0(“0}Κ*, -SpOhNCRlÇ^jOR8, -NR8R8,: wM(R*)C(-0)R*. -N(Rä)C(-OlORa, -Nt R")< ’{«Ö)NR*R* PlfR*)€pBR*)NÄ*,. -:B(Is)S:(^0);NRsRa, -BRsCMalkilNR*R*, -NR'O.„alküOR5. Csalid;, fen!;, benzd, fétefeadl és Moro-oikkäs: közöl vál&szíött, ahol a Cj^alkií, -fesltí, henal, hetesxTaril és hetetocikios -tovább szufesztshi&b 0. 1, 2 vagy 3 sanbSgti&eísssol, aáfely haló, Ci.^fcűoaifeil, etano, nitro, -€<=“0)R*, -C(--O)OR!l, Ό “OlNR^Rk C("=NRS)N'RÄR8 >OBÍ, *Ú€F pÖ}R*, -OC(~ö)NRaRa, -OCeOlNtR^iSe-O)^, -OC^alkilNRaRa, -C.X;, .aîkilOR*, -SR*, :*5(«0}R% -•Sí-OgR5, -‘Sí-OjNR^ -S^feNÍR^CHlip15,, -St-OhNtR^a^OpRÍ -S(^N(R^|*<>)NR*K*.· -NR*Re. -NíR3)C(K:0)Ra, ^(I^ef-OIORÍ, -N^í.^-0}NRaRa< -N(R*)C(“NR*)NR*R*, -N(R*)S(-0)2BR*R* -NRAe2,mMORs közöl választott; vagy Rs jelentése tellett, feszbeo íglRett víígy Mhetlet; 5», 6* vagy 7'tagó, M, 0 vagy S közül ydassttotk 1, i, 2., 3 yagÿ 4: &toínot:tartabuazó toottosÉlosos gyűrő, de öem tartaímaz egynél toll Ö vagy 8 atotttoí,: aboí a gyqrü hozzáfethetö szeoatottgai ö, 1; vagy 2 oxo vagy tiaxo csoporttal: szabsztltuáltak, altoía gyürü B,, 3,2,3 Vi^: 4 .S23tis2toáiU fedte, C irkálóé Ildi, ciaao, ttitro, -C(-0)R*, -0(^0)0¾ 'Ct'-OpRlRí, PH4RS}B«, -ÖR8, -OGpÖjR^ -ÖÍ^ÖjNRP*, -OayOp(RnS( <0jRö -«atliÄ <QGmah RtlOR8, -SR8, -S(~Ö)R3, PpO)p?J: -SH1NÄ -SCKljPCRnCC-OlR8, -SH<))P(R8)C(-O)0R:i: PH>)ÄH3)CO<))lN®CR8: prR3, .MV; -MpOCHBOR8, -NfR8)- C(=-NR3)BRSRS, --BtiriSpQiprR8, -'NR3Cj.yükllN:R8R8 és -NR3Q>.öalkilOR3 közül vá lasztott; R! ! jefeatése M vagy C^alkil; Ra jdesíése mirKiea esePsea, egymástól ifeggetlessöl, 11 vagy Rb; és IIs jdestese m&úm «sæfee», egymástól taggedesäl, ímö, beazil vagy Cj^alkii, a IPetl, berrnil és Cj^alkü 0. 1, 2 vagy 3 ssabszíáae®«) sxataftaáK. lefed, és a ss'efesdifeseas halo, -CjuAílj Cs.jb&baMI» ΌΟί,.^ΙΙίϋ, 'MH;;, ^KCmsSî», ·Μ<€í,4aBíií}€:í.«aikP kézál választolt 2, ,4z Ϊ. Igétypoat szentfei kö vetkézé szerkezeti képteíü vegyülsl;
- 3. Az L Sgenypoßt szerinti, következő szerkezeti kép-tető vegyetek-
- 4. Az Î, tgéííypöMszeíisti következő szetiesett képiető vegyőtef:
- 5, M L igénypont szednss ve-gyölet, afeoli R! jelentése F, Cl vagy Sr; és a értéke 0. &M i. igénypont SKemti yegyßtet, ahoi R! jelentése 0 vagy Í ïi! szubsruitueassdsmMzätoMtfeniks* a feni Ci, I, 2 vagy 3 s^fcsatíteesssel tovább halo» nitro, ciano, €;. ^alkil, €€:.4&ΓκΙ1, OC^iMalklÄCiÄ, NÎC:; .4si:kii>C.;.4aIksJ: és CMhstoafkM fösüi Mksxto&
- 7, Az L %éftÿge8t vrerMt vegyik*, ahokR1 jekstése kärveüea Mfesset vagy okígánea ksrmzí&l kaja ösoíoiib tóiietb réxaben-tfôiîvfVvagy teliteken >.. 6- vagy 7-tagä, N', D vagy S közül választott, i, 2,3 vagy 4 sttnset ísnateszái». de egysei s§bb 0 vagyis atontot nen; iastaltnazó rsgiissaiMöses gyitrik iW a gysM tmsfek kékésre álló szénatomjai 0, I vagy 3 am vagy iloxo essforUal sxabsKtifeÄk, fel a gyikf § vagy l io SKsbsziibíbösSd SíbbsKtiíuált, ás a gytrü tovább »ánbsatiátáli ë.,·. 1, 2: vagy 3 sanbsxktaénsseij aníejy egÿniasîôt feggíklenül a kbvstk&Ä lbzä! válásaiéit: halo,. nitre, tism, C^sSM, ÖQ4ÄM, MCi4â}ki)C<.#ïkil «s CiJbdo&Mi'y g. As: 1. igénypont szerinti, kővetkező szerkezek képiéül vegyüistvagy a> b) ás <?) bánts«!yíká»ek Mrœdy gybgyászatilsg slfögü$»® sfeä· 9 Ag ;gányx»i5t sserinö vegyük* szabad bázis femfejsban' 'ϋϊι Aa 1*9. igénypontok. feánaelyike szAKki vegyűietet és gyágydszablag: «IpgMbató Éigííésszert vagy hordozói tartaknaxó gyógyászati készítmény. II , Az ÏA. igetîypsbôk bfeielyiké szeséái vegyül# rhemaisldid artîihssî, spoiixMiiis aækylapiæM** osieoarbitm, p^oáékm |>S2&#Ä gyulladásos betegségek és sstósa»* ^betegségeik, gyulladási bélb«®gseg«^ gyulfeddsos î«!Ç8Âi«s^» gyulladásos vagy tefc8>$ l^ylélyág-íesdsIfertöSsegek, bár panaszok gy#laáásos elemekkel kÄkus gyulladásos MI#xáok, autoimrnuö betegségek, ssisziémás îyji órylhfiOiáfesós ISLE):, myaatííesia grakts,: yeyb?aiotd aidrítisz, akut disszidált ebcspkateisyslitis, Mopá&ás troïisbo(Ok>jïeb||$ p«â|îarif, sskteréiss: multiplex, Stógiési-sziudréíua és aetoimmüb IäoIÄss süéttiía, allergiás állapotok# tűlébAkeííység keMésám idrl#» alkslraazásfá, II, Az W. }0iÿpœêï!k bármelyike szeripi vegyuleí p l 10§ aMvI^ssalMzvgfkg«, apái iiggŐ vágy ab-hoz kapcsolódé Ä'Äsi^s%i?attoaS.ais:^masÄ^> Í3. M 1-9. igéaypffiíííok bámtelyifce szermis vegyulet vaslagbélrák, glioi#s#áma, vziáomeiééHs Mm-:#53ga, bsgaíseetolám fék, ííklórák, msktftóssta, vesese|í-ksrdsófSa, palxstmrjgy-kiim, imíöma, iimfopro·· ']%$mÉ$·. w^élíesess^elj Ötsejtss tüdSrék, pikkelyes sejtes ISdirák, gbbi^gj epíískak, prosx!»tik, peíe%^k·· yâk. pébayakrák, leukémia, akatdiékíM |öiké»kas myelödysplpiás sgmdrdtsrav sfildopmliletstik ttiegbetegedé-sífkj krónikus myelolá: leukémia, Τ#ρ|ί«& akiit )te|pblssxk>s leakémia, B- sejtes stet bmíobIaá#ós leukémia, oesxvHodgkm lipîiiSi&a, B-seiliesÄÄ^didÄPä '^atpr#;:k««»í^élTO történd .alkalmsaim
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91956807P | 2007-03-23 | 2007-03-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE028954T2 true HUE028954T2 (hu) | 2017-01-30 |
Family
ID=39645618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE08727163A HUE028954T2 (hu) | 2007-03-23 | 2008-03-24 | Heterociklusos vegyületek és alkalmazásuk |
Country Status (24)
Country | Link |
---|---|
US (6) | US8193199B2 (hu) |
EP (2) | EP2137186B1 (hu) |
JP (2) | JP5527761B2 (hu) |
KR (1) | KR101504773B1 (hu) |
CN (1) | CN101715453B (hu) |
AU (1) | AU2008231304B2 (hu) |
BR (1) | BRPI0809141A2 (hu) |
CA (1) | CA2681136C (hu) |
CR (2) | CR11053A (hu) |
DK (1) | DK2137186T3 (hu) |
EA (1) | EA017389B1 (hu) |
ES (1) | ES2563458T3 (hu) |
HR (1) | HRP20160350T1 (hu) |
HU (1) | HUE028954T2 (hu) |
IL (1) | IL200867A (hu) |
MX (1) | MX2009009968A (hu) |
NZ (1) | NZ579834A (hu) |
PL (1) | PL2137186T3 (hu) |
PT (1) | PT2137186E (hu) |
RS (1) | RS54706B1 (hu) |
SI (1) | SI2137186T1 (hu) |
UA (1) | UA98955C2 (hu) |
WO (1) | WO2008118468A1 (hu) |
ZA (1) | ZA201308294B (hu) |
Families Citing this family (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1831225A2 (en) | 2004-11-19 | 2007-09-12 | The Regents of the University of California | Anti-inflammatory pyrazolopyrimidines |
PT2004654E (pt) | 2006-04-04 | 2013-08-27 | Univ California | Derivados de pirazolopirimidina para utilização como antagonistas da quinase |
CA2680853C (en) * | 2007-03-23 | 2012-07-17 | Amgen Inc. | 3- substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors |
NZ579834A (en) * | 2007-03-23 | 2012-03-30 | Amgen Inc | Heterocyclic compounds as selective inhibitors of PI3K activity |
GB2467670B (en) | 2007-10-04 | 2012-08-01 | Intellikine Inc | Chemical entities and therapeutic uses thereof |
ES2587738T3 (es) | 2007-12-21 | 2016-10-26 | Ucb Biopharma Sprl | Derivados de quinoxalina y quinolina como inhibidores de quinasa |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
AU2009204483B2 (en) | 2008-01-04 | 2014-03-13 | Intellikine, Llc | Certain chemical entities, compositions and methods |
JP5547099B2 (ja) | 2008-03-14 | 2014-07-09 | インテリカイン, エルエルシー | キナーゼ阻害剤および使用方法 |
WO2009114874A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
EP2307400B1 (en) | 2008-05-30 | 2014-04-23 | Amgen, Inc | Inhibitors of pi3 kinase |
US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
AU2009268611B2 (en) | 2008-07-08 | 2015-04-09 | Intellikine, Llc | Kinase inhibitors and methods of use |
EP2346508B1 (en) | 2008-09-26 | 2016-08-24 | Intellikine, LLC | Heterocyclic kinase inhibitors |
JP5819195B2 (ja) | 2008-10-16 | 2015-11-18 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 融合環ヘテロアリールキナーゼ阻害剤 |
GB0819593D0 (en) | 2008-10-24 | 2008-12-03 | Ucb Pharma Sa | Therapeutic agents |
US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
GB0821693D0 (en) * | 2008-11-27 | 2008-12-31 | Ucb Pharma Sa | Therapeutic agents |
US8592415B2 (en) * | 2009-02-11 | 2013-11-26 | Reaction Biology Corp. | Selective kinase inhibitors |
ES2598358T3 (es) | 2009-02-13 | 2017-01-27 | Ucb Pharma, S.A. | Derivados de quinolina como inhibidores de PI3K quinasa |
ES2568508T3 (es) | 2009-03-06 | 2016-04-29 | Ucb Biopharma Sprl | Derivados de triazina como inhibidores de cinasas |
EP2426135A4 (en) | 2009-04-27 | 2013-02-20 | Shionogi & Co | UREA DERIVATIVE WITH PI3K-INHIBITING EFFECT |
CA2760791C (en) | 2009-05-07 | 2017-06-20 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
GB0908957D0 (en) * | 2009-05-22 | 2009-07-01 | Ucb Pharma Sa | Therapeutic agents |
EP2445900B1 (en) | 2009-06-25 | 2016-03-02 | Amgen, Inc | Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases |
AU2010273816B2 (en) | 2009-06-29 | 2015-07-09 | Incyte Holdings Corporation | Pyrimidinones as PI3K inhibitors |
TW201111385A (en) * | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
WO2011058111A1 (en) | 2009-11-12 | 2011-05-19 | Ucb Pharma S.A. | Aminopurine derivatives as kinase inhibitors |
WO2011058109A1 (en) | 2009-11-12 | 2011-05-19 | Ucb Pharma S.A. | Fused bicyclic pyrrole and imidazole derivatives as kinase inhibitors |
WO2011058112A1 (en) | 2009-11-12 | 2011-05-19 | Ucb Pharma S.A. | Fused bicyclic pyrazole derivatives as kinase inhibitors |
EP2499144B1 (en) | 2009-11-12 | 2013-10-23 | UCB Pharma, S.A. | Quinoline and quinoxaline derivatives as kinase inhibitors |
ES2520345T3 (es) | 2009-11-12 | 2014-11-11 | Ucb Pharma, S.A. | Derivados de quinolina y quinoxalina en calidad de inhibidores de quinasa |
US8957090B2 (en) | 2009-11-12 | 2015-02-17 | Ucb Pharma S.A. | Fused bicyclic pyridine and pyrazine derivatives as kinase inhibitors |
EP2513109A1 (en) * | 2009-12-18 | 2012-10-24 | Amgen Inc. | Heterocyclic compounds and their uses |
WO2011075630A1 (en) * | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors |
WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
WO2011093365A1 (ja) * | 2010-01-27 | 2011-08-04 | 協和発酵キリン株式会社 | 含窒素複素環化合物 |
WO2011130342A1 (en) | 2010-04-14 | 2011-10-20 | Incyte Corporation | FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS |
WO2011146882A1 (en) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Chemical compounds, compositions and methods for kinase modulation |
JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
EP2588473A1 (en) * | 2010-06-30 | 2013-05-08 | Amgen Inc. | Nitrogen containing heterocyclic compounds as pik3 -delta inhibitors |
AU2011272853A1 (en) * | 2010-07-01 | 2013-01-10 | Amgen Inc. | Heterocyclic compounds and their use as inhibitors of PI3K activity |
CA2803259A1 (en) * | 2010-07-01 | 2012-01-05 | Amgen Inc. | Heterocyclic compounds and their use as inhibitors of pi3k activity |
AU2011272850A1 (en) | 2010-07-02 | 2013-01-10 | Amgen Inc. | Heterocyclic compounds and their use as inhibitors of PI3K activity |
AR082799A1 (es) * | 2010-09-08 | 2013-01-09 | Ucb Pharma Sa | Derivados de quinolina y quinoxalina como inhibidores de quinasa |
AU2011302196B2 (en) * | 2010-09-14 | 2016-04-28 | Exelixis, Inc. | Inhibitors of PI3K-delta and methods of their use and manufacture |
JP2013541591A (ja) * | 2010-11-04 | 2013-11-14 | アムジエン・インコーポレーテツド | 複素環化合物およびそれらの使用 |
JP2013545749A (ja) * | 2010-11-10 | 2013-12-26 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | 複素環化合物及びその使用 |
US8765768B2 (en) * | 2010-11-17 | 2014-07-01 | Amgen Inc. | Heterocyclic compounds and their uses |
EP2655374B1 (en) | 2010-12-20 | 2019-10-23 | Incyte Holdings Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
BR112013017670B1 (pt) | 2011-01-10 | 2022-07-19 | Infinity Pharmaceuticals, Inc | Processos de preparação de isoquinolinonas e formas sólidas de isoquinolinonas |
CN106619647A (zh) | 2011-02-23 | 2017-05-10 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 |
WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
WO2013012915A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
KR20140063605A (ko) | 2011-07-19 | 2014-05-27 | 인피니티 파마슈티칼스, 인코포레이티드 | 헤테로사이클릭 화합물 및 그의 용도 |
MX2014002542A (es) | 2011-08-29 | 2014-07-09 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos. |
MX370814B (es) | 2011-09-02 | 2020-01-08 | Univ California | Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas. |
AR087760A1 (es) | 2011-09-02 | 2014-04-16 | Incyte Corp | Heterociclilaminas como inhibidores de pi3k |
JP6093770B2 (ja) | 2011-09-27 | 2017-03-08 | アムジエン・インコーポレーテツド | 癌の治療のためのmdm2阻害剤としての複素環化合物 |
EP2763994A4 (en) * | 2011-10-04 | 2015-08-26 | Gilead Calistoga Llc | NEW QUINOXALINE INHIBITORS OF THE PI3K PATH |
DK2790705T3 (en) | 2011-12-15 | 2018-03-12 | Novartis Ag | Use of inhibitors of the activity or function of PI3K |
US20150011569A1 (en) * | 2011-12-15 | 2015-01-08 | Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine | NOVEL P13K p110 INHIBITORS AND METHODS OF USE THEREOF |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
BR112015006828A8 (pt) | 2012-09-26 | 2019-09-17 | Univ California | composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1 |
MX368833B (es) * | 2013-01-31 | 2019-10-18 | Vertex Pharma | Derivados de quinolina y quinazolina amidas como inhibidores de canales de sodio nav1.8 y el uso de los mismos en el tratamiento del dolor. |
AU2014219075C1 (en) | 2013-02-19 | 2018-09-06 | Amgen Inc. | Cis-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
AU2014236812B2 (en) | 2013-03-14 | 2018-03-01 | Amgen Inc. | Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
ES2900806T3 (es) | 2013-10-04 | 2022-03-18 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos y usos de los mismos |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EA036942B1 (ru) | 2013-11-11 | 2021-01-18 | Эмджен Инк. | Применение amg232 в комбинации с цитарабином или децитабином для лечения острого миелогенного лейкоза |
US10328080B2 (en) | 2013-12-05 | 2019-06-25 | Acerta Pharma, B.V. | Therapeutic combination of PI3K inhibitor and a BTK inhibitor |
DK3119397T3 (da) | 2014-03-19 | 2022-03-28 | Infinity Pharmaceuticals Inc | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser |
US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2015171725A1 (en) | 2014-05-06 | 2015-11-12 | Amgen Inc. | Hydrate, crystalline hydrate and crystalline anhydrate forms of n-((1s)-1-(7-fluoro-2-(2-pyridinyl)-3-quinolinyl)ethyl)-9h-purin-6-amine, pharmaceutical compositions containing them and methods for treating cancer. |
CN104086551B (zh) * | 2014-06-06 | 2016-09-21 | 人福医药集团股份公司 | 化合物及其制备方法和用途 |
US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
JP6291601B2 (ja) | 2014-07-04 | 2018-03-14 | ルピン・リミテッド | Pi3k阻害剤としてのキノリジノン誘導体 |
EP2974729A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
HUE059131T2 (hu) | 2014-08-11 | 2022-10-28 | Acerta Pharma Bv | BTK-inhibitor, PD-1-inhibitor és/vagy PD-L1-inhibitor terápiás kombinációja |
WO2016024232A1 (en) | 2014-08-11 | 2016-02-18 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor |
EP3179991B1 (en) | 2014-08-11 | 2021-10-06 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US10626094B2 (en) * | 2014-10-14 | 2020-04-21 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof |
EA037663B1 (ru) | 2015-01-16 | 2021-04-28 | Те Дженерал Хоспитал Корпорейшн | СОЕДИНЕНИЯ ДЛЯ УЛУЧШЕНИЯ СПЛАЙСИНГА мРНК |
US9637488B2 (en) | 2015-01-29 | 2017-05-02 | Fuqiang Ruan | Heterocyclic compounds as inhibitors of class I PI3KS |
PT3262046T (pt) | 2015-02-27 | 2020-12-24 | Incyte Corp | Sais de inibidor de pi3k e processos para a sua preparação |
CN106008479B (zh) * | 2015-03-06 | 2020-01-10 | 南京圣和药业股份有限公司 | 作为磷脂酰肌醇3-激酶δ抑制剂的取代嘧啶类化合物及其应用 |
GB201506786D0 (en) * | 2015-04-21 | 2015-06-03 | Ucb Biopharma Sprl | Therapeutic use |
US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
KR20180058741A (ko) | 2015-09-14 | 2018-06-01 | 인피니티 파마슈티칼스, 인코포레이티드 | 이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법 |
WO2017091681A1 (en) | 2015-11-24 | 2017-06-01 | Aclaris Therapeutics, Inc. | Selective kinase inhibitors |
CA3013490C (en) * | 2016-03-05 | 2021-09-14 | Hangzhou Zhengxiang Pharmaceuticals Co., Ltd. | Quinoline analogs as phosphatidylinositol 3-kinase inhibitors |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
AU2017281797A1 (en) | 2016-06-24 | 2019-01-24 | Infinity Pharmaceuticals, Inc. | Combination therapies |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
CN108069899B (zh) * | 2016-11-18 | 2021-01-08 | 中国科学院大连化学物理研究所 | 一种制备2,3-取代喹啉类衍生物的方法 |
WO2018204176A1 (en) | 2017-05-01 | 2018-11-08 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
US10442799B1 (en) | 2018-04-07 | 2019-10-15 | Fuqiang Ruan | Heterocyclic compounds and uses thereof |
MA52501A (fr) | 2018-05-04 | 2021-03-10 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
CN114144414A (zh) | 2019-05-21 | 2022-03-04 | 美国安进公司 | 固态形式 |
CN112574176B (zh) * | 2019-09-27 | 2024-03-15 | 隆泰申医药科技(南京)有限公司 | 一种杂芳基类化合物及其应用 |
EP4045047A1 (en) | 2019-10-15 | 2022-08-24 | Amgen Inc. | Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers |
WO2021126816A1 (en) | 2019-12-16 | 2021-06-24 | Amgen Inc. | Dosing regimen of a kras g12c inhibitor |
CN114276326B (zh) * | 2021-03-09 | 2022-11-11 | 南京征祥医药有限公司 | 喹啉化合物的盐及制备方法和应用 |
CN113218936B (zh) * | 2021-06-07 | 2021-09-10 | 江苏欣诺科催化剂有限公司 | 锇酸钾的纯度检测方法 |
WO2023016477A1 (en) * | 2021-08-11 | 2023-02-16 | Taizhou Eoc Pharma Co., Ltd. | A cyclin-dependent kinase inhibitor |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
US6043062A (en) | 1995-02-17 | 2000-03-28 | The Regents Of The University Of California | Constitutively active phosphatidylinositol 3-kinase and uses thereof |
GB9611460D0 (en) | 1996-06-01 | 1996-08-07 | Ludwig Inst Cancer Res | Novel lipid kinase |
US5858753A (en) | 1996-11-25 | 1999-01-12 | Icos Corporation | Lipid kinase |
US5822910A (en) | 1997-10-02 | 1998-10-20 | Shewmake; I. W. | Fishing line tensioning device |
WO2001060816A1 (en) * | 2000-02-17 | 2001-08-23 | Amgen Inc. | Kinase inhibitors |
US20050187389A1 (en) * | 2004-01-13 | 2005-08-25 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
US8076338B2 (en) * | 2004-04-23 | 2011-12-13 | Exelixis, Inc. | Kinase modulators and methods of use |
WO2006114180A1 (de) * | 2005-04-25 | 2006-11-02 | Merck Patent Gmbh | Neuartige aza-heterozyklen als kinase-inhibitoren |
US20090170848A1 (en) | 2006-03-02 | 2009-07-02 | Smithkline Beecham Corporation | Thiazolones for use as pi3 kinase inhibitors |
WO2007103759A2 (en) | 2006-03-02 | 2007-09-13 | Smithkline Beecham Corporation | Thiazolones for use as pi3 kinase inhibitors |
US20080221161A1 (en) | 2007-02-09 | 2008-09-11 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 for treatment of disease |
NZ579834A (en) * | 2007-03-23 | 2012-03-30 | Amgen Inc | Heterocyclic compounds as selective inhibitors of PI3K activity |
CA2700088A1 (en) | 2007-09-26 | 2009-04-02 | Astellas Pharma Inc. | Quinolone derivative |
ES2587738T3 (es) * | 2007-12-21 | 2016-10-26 | Ucb Biopharma Sprl | Derivados de quinoxalina y quinolina como inhibidores de quinasa |
EP2346508B1 (en) * | 2008-09-26 | 2016-08-24 | Intellikine, LLC | Heterocyclic kinase inhibitors |
GB0819593D0 (en) * | 2008-10-24 | 2008-12-03 | Ucb Pharma Sa | Therapeutic agents |
GB0821693D0 (en) * | 2008-11-27 | 2008-12-31 | Ucb Pharma Sa | Therapeutic agents |
ES2598358T3 (es) | 2009-02-13 | 2017-01-27 | Ucb Pharma, S.A. | Derivados de quinolina como inhibidores de PI3K quinasa |
CA2760791C (en) * | 2009-05-07 | 2017-06-20 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
EP2445900B1 (en) * | 2009-06-25 | 2016-03-02 | Amgen, Inc | Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases |
US8957090B2 (en) | 2009-11-12 | 2015-02-17 | Ucb Pharma S.A. | Fused bicyclic pyridine and pyrazine derivatives as kinase inhibitors |
EP2513109A1 (en) | 2009-12-18 | 2012-10-24 | Amgen Inc. | Heterocyclic compounds and their uses |
-
2008
- 2008-03-24 NZ NZ579834A patent/NZ579834A/en unknown
- 2008-03-24 JP JP2009554600A patent/JP5527761B2/ja active Active
- 2008-03-24 UA UAA200910741A patent/UA98955C2/ru unknown
- 2008-03-24 EA EA200901276A patent/EA017389B1/ru not_active IP Right Cessation
- 2008-03-24 RS RS20160208A patent/RS54706B1/en unknown
- 2008-03-24 PT PT87271631T patent/PT2137186E/pt unknown
- 2008-03-24 HU HUE08727163A patent/HUE028954T2/hu unknown
- 2008-03-24 CN CN2008800170109A patent/CN101715453B/zh active Active
- 2008-03-24 US US12/079,406 patent/US8193199B2/en active Active
- 2008-03-24 EP EP08727163.1A patent/EP2137186B1/en active Active
- 2008-03-24 SI SI200831591T patent/SI2137186T1/sl unknown
- 2008-03-24 EP EP16152820.3A patent/EP3045458A1/en not_active Withdrawn
- 2008-03-24 MX MX2009009968A patent/MX2009009968A/es active IP Right Grant
- 2008-03-24 BR BRPI0809141-2A patent/BRPI0809141A2/pt not_active Application Discontinuation
- 2008-03-24 AU AU2008231304A patent/AU2008231304B2/en active Active
- 2008-03-24 KR KR1020097022066A patent/KR101504773B1/ko active IP Right Grant
- 2008-03-24 CA CA2681136A patent/CA2681136C/en active Active
- 2008-03-24 ES ES08727163.1T patent/ES2563458T3/es active Active
- 2008-03-24 PL PL08727163.1T patent/PL2137186T3/pl unknown
- 2008-03-24 WO PCT/US2008/003962 patent/WO2008118468A1/en active Application Filing
- 2008-03-24 DK DK08727163.1T patent/DK2137186T3/en active
-
2009
- 2009-09-10 IL IL200867A patent/IL200867A/en active IP Right Grant
- 2009-10-05 CR CR11053A patent/CR11053A/es unknown
-
2010
- 2010-07-21 CR CR11582A patent/CR11582A/es unknown
-
2012
- 2012-05-10 US US13/468,234 patent/US8901135B2/en active Active
- 2012-05-10 US US13/468,212 patent/US8586739B2/en active Active
-
2013
- 2013-10-22 JP JP2013218925A patent/JP5819382B2/ja active Active
- 2013-11-05 ZA ZA2013/08294A patent/ZA201308294B/en unknown
-
2014
- 2014-10-22 US US14/520,899 patent/US9873701B2/en active Active
-
2016
- 2016-04-06 HR HRP20160350TT patent/HRP20160350T1/hr unknown
-
2017
- 2017-12-13 US US15/841,153 patent/US20180105532A1/en not_active Abandoned
-
2019
- 2019-10-17 US US16/656,328 patent/US20200048265A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2137186B1 (en) | Heterocyclic compounds and their uses | |
US9873704B2 (en) | Heterocyclic compounds and their uses | |
CA2680783C (en) | Heterocyclic compounds and their uses | |
US8754089B2 (en) | Heterocyclic compounds and their uses | |
US8835432B2 (en) | Heterocyclic compounds and their uses |